A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
21 day cycle: treatment until death, lost to follow up or withdrawal
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CAUY922A2202
NCT01084330
April 2010
May 2012
Name | Location |
---|---|
Horizon Oncology Center | Lafayette, Indiana 47905 |
Arena Oncology Associates, PC Dept.ofArenaOncologyAssoc(2) | Lake Success, New York 11042 |
Tyler Cancer Center Dept.ofTylerCancerCtr. (2) | Tyler, Texas 75702 |
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU | Baltimore, Maryland 21231 |
UCLA/ University of California Los Angeles Dept. of UCLA (4) | Los Angeles, California 90095 |
USC/Kenneth Norris Comprehensive Cancer Center USC/Norris | Los Angeles, California 90033 |
University of California at Los Angeles Dept. of UCLA (4) | Los Angeles, California 90095 |
Baylor College of Medicine Baylor Texas Oncology | Dallas, Texas 75246 |